BPC-157 Drug Interactions with Common Medications

No formal drug interaction study has ever been conducted for BPC-157, in any species, with any medication. When readers ask about bpc 157 drug interactions, the honest answer is that every interaction listed below is either theoretical, extrapolated from the peptide's known mechanisms in animal models, or drawn from unverified community reports. We compiled them because the questions are legitimate and the pharmacological reasoning behind each concern is worth understanding. If you take prescription medications, read this page and then talk to your prescriber. For the broader safety picture, start with our BPC-157 safety overview.

BPC-157 Drug Interactions - Known and Theoretical

Why Most Interactions Are Theoretical

Interaction data requires controlled studies where the compound is co-administered with a medication and measurable endpoints are tracked. BPC-157 has never been through this process. What we have are animal studies showing BPC-157 modulates the nitric oxide system, dopaminergic pathways, and other signaling cascades. When a medication also acts on one of those systems, we can identify a plausible overlap. Plausible is not proven.

No Human Pharmacokinetic Data Published

No published paper has measured BPC-157's absorption, distribution, metabolism or excretion in humans. A pharmacokinetics study in rats and dogs provided the first rigorous PK data, showing a plasma half-life under 30 minutes. Without human PK data, we cannot predict how BPC-157 behaves alongside other drugs. Every interaction concern below carries that caveat.

Blood Pressure Medications

ACE Inhibitors and ARBs

ACE inhibitors (lisinopril, enalapril) and ARBs (losartan, valsartan) lower blood pressure via the renin-angiotensin system. BPC-157 modulates nitric oxide, a separate but related pathway. In animal models, BPC-157 normalized both elevated and depressed blood pressure, suggesting a modulatory rather than unidirectional effect. The theoretical concern is additive hypotension: both compounds pushing blood pressure lower than either would alone. No study has tested this. Users on ACE inhibitors who report dizziness after BPC-157 injection should consider additive vasodilation as a possible factor. See our BPC-157 and blood pressure page for more detail.

Calcium Channel Blockers

Calcium channel blockers like amlodipine and nifedipine reduce blood pressure by relaxing vascular smooth muscle. BPC-157's nitric oxide activity acts on the same tissue. The mechanistic overlap is clear, even though it has never been measured. This category of bpc 157 drug interactions is among the most asked about. Users who take calcium channel blockers and notice increased lightheadedness or flushing after starting BPC-157 may be seeing this overlap in practice.

Blood Thinners and Anticoagulants

Warfarin and Heparin

BPC-157 promotes angiogenesis and influences wound healing pathways that overlap with coagulation. No study has examined whether it alters the activity of warfarin, heparin or other anticoagulants. The theoretical concern is twofold: the peptide could interfere with anticoagulant efficacy by promoting clotting-adjacent pathways, or amplify bleeding risk by increasing local vascularization. Neither scenario has been observed. People on therapeutic anticoagulation have narrow safety margins, and any uncharacterized compound introduces risk. For context, see our full risks page.

Aspirin and NSAIDs

Aspirin and NSAIDs are among the medications most commonly co-used with BPC-157, based on community reports. Multiple animal studies tested BPC-157 against NSAID-induced gastric damage and found the peptide counteracted mucosal lesions caused by diclofenac and ibuprofen in rats. This is protective rather than harmful in the animal data. However, the research tested BPC-157 as a treatment for existing NSAID damage, not as a concurrent supplement. Whether the peptide alters NSAID pharmacokinetics is unknown. Community reports from users taking both are generally unremarkable. For related information on bpc 157 and nsaids specifically, our side effect reduction guide includes practical notes.

Psychiatric Medications

SSRIs and Serotonergic Drugs

BPC-157 influences the dopamine system in animal models, and a 2025 review noted interactions with serotonergic pathways as well. SSRIs (fluoxetine, sertraline) increase serotonin by blocking reuptake. If BPC-157 independently modulates serotonin signaling, the combination could theoretically alter mood or GI function unpredictably. Serotonin syndrome is the extreme concern, though no evidence links BPC-157 to it. Users on SSRIs who report mood changes during BPC-157 use should discuss this with their prescriber.

Benzodiazepines

Benzodiazepines act on GABA receptors to produce sedation and anxiolysis. BPC-157's documented effects on dopamine turnover and nitric oxide do not directly overlap with GABAergic mechanisms, so the theoretical interaction risk is lower here than with serotonergic drugs. Both compounds can cause dizziness (BPC-157 transiently, benzodiazepines more persistently), and additive sedation is a general concern when combining CNS-active substances. No specific interaction data exists.

Hormones and Hormone-Modulating Drugs

Corticosteroids

Corticosteroids (prednisone, dexamethasone) suppress inflammation and immune function. BPC-157 modulates inflammatory pathways and promotes tissue repair. These are opposing forces in some contexts: corticosteroids slow wound healing, while BPC-157 accelerates it in animal models. Whether the two cancel each other out or have no meaningful interaction is completely unstudied. People using corticosteroids for autoimmune conditions should be cautious about adding any immunomodulatory compound. Our contraindications page covers this further.

Thyroid Medications

Levothyroxine and similar thyroid hormones have narrow therapeutic windows. No data suggests BPC-157 affects thyroid hormone levels or thyroid function. The peptide has not shown affinity for thyroid receptors in any published study. We include this entry because we receive reader questions about it regularly, not because there is pharmacological reason to expect an interaction.

Supplements and Over-the-Counter Products

Other Peptides and Growth Factors

Stacking BPC-157 with other peptides, particularly TB-500, is common in online communities. No interaction study between BPC-157 and TB-500 (or any other peptide) has been published. The concern is unpredictable amplification: two growth-promoting peptides taken together could produce effects that neither would produce alone. This is speculative but pharmacologically reasonable. For context on recovery compounds, see our BPC-157 vs steroids comparison.

Herbal Supplements with Blood-Thinning Properties

Fish oil, turmeric (curcumin), ginkgo biloba and garlic supplements all have mild anticoagulant or antiplatelet activity. Combined with BPC-157's effects on vascularization, the theoretical risk is altered bleeding or bruising at injection sites. Users on these supplements who inject BPC-157 occasionally report more bruising than expected. Whether that reflects a real interaction or normal injection-site variation is unclear. We cover bpc 157 and alcohol in a separate guide, since alcohol also has blood-thinning properties and the overlap question comes up frequently.

What to Tell Your Doctor

Bring the product label or vendor page. Explain that BPC-157 is a synthetic pentadecapeptide sold as a research chemical, with no human clinical trial data. Mention that the FDA has flagged it as a bulk drug substance that may present safety risks in compounding. This gives your prescriber enough context to make informed decisions.

If you are on medications with narrow therapeutic indices, including warfarin, lithium, thyroid hormones or immunosuppressants, the need for disclosure is even greater. Any unapproved compound could alter the balance these drugs maintain. Consult your doctor before combining BPC-157 with any prescription medication, and do not adjust your prescribed regimen based on peptide use.